Our fundamental technology targets:
•High sensitivity and specificity •Ultrasmall sample volumes •Deployable devices •Multiplex with spatial resolution •In-vivo continuous monitoring |
Our sensing approaches:
•Immunosensing •Aptamer based biosensing •CRISPR/Cas systems based biosensing •Molecularly imprinted polymers based biosensing |
Our signal readout platforms:
•Smartphone readout (fluorescence, colorimetry) •Consumer electronics such as glucose meters (electrochemistry) •Fluorescence or laser scanning microscopy •Wireless/Clouds |
We have developed a range of sensing platforms for detection of cancer biomarkers, hormones, and cell secreted products, such as cytokines, insulin, glucose, cortisol, HbA1c, botulinum neurotoxin type A, troponin-I and exosomes. These sensing platforms are universal, and can be re-purposed for detection of a spectrum of analytes.